{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever \\>38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes \\>20%.\n\nCMML, AML, ALL \\>30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.\n\nCLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.\n\nNHL \\>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.\n\nMM\n\n≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.","groups":[{"description":"Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG000","title":"Treatment (DLI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year after DLI","title":"Incidence of Relapse/Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}